Source comparison
Head-to-Head vs. Cross-Trial: The Only Fair Comparisons
This is the honesty centerpiece of the comparison, and it can be stated in one sentence: no published randomized controlled trial has ever directly compared tesamorelin against sermorelin. Every comparison you will read — including this one — is indirect, asse
This comparison does not assign a generated winner or score.
- This is the honesty centerpiece of the comparison, and it can be stated in one sentence: no published randomized controlled trial has ever directly compared tesamorelin against sermorelin. Every comparison you will read — including this one — is indirect, assembled from separate trials run in different populations, at different times, with different endpoints. That is a legitimate way to describe two molecules, but it is a weak basis for claiming one is “better” than the other for any shared purpose.
- The table below is explicit about what kind of evidence backs each comparison you might want to make. Notice how quickly the “evidence strength” column drops once you leave each drug’s own trials.
- Tesamorelin vs placebo (visceral fat, HIV lipodystrophy)
- Multiple double-blind, placebo-controlled Phase 3 RCTs (~400+ patients)
- Strong (direct)
- VAT reduced ~15% at 26 wk, ~18% at 52 wk; reverses on stopping[1][3]
- Sermorelin vs placebo/comparator (pediatric GHD)
- Older human studies; diagnostic and growth-velocity data
- Moderate, dated (human but not modern RCT)
- Increased height velocity in some GH-deficient children[5]
- Tesamorelin vs sermorelin (any shared endpoint)
- None — no direct trial exists
- Not established (cross-trial inference only)
- Cannot be ranked head-to-head; populations and endpoints differ
- Either peptide for adult “anti-aging” / general fat loss
- No adequate RCTs
- Not established
- Mechanistic extrapolation only; not a proven outcome
- The practical takeaway: it is accurate to say tesamorelin has the higher-quality and more recent human evidence, because that describes each drug’s own trial record. It is not accurate to say a trial proved tesamorelin outperforms sermorelin, because no such trial was ever run. Keeping those two statements distinct is the difference between honest reading and marketing.